GCVI Summit 2018
Skip Content

27 July 2012

Cell Medica raises $26.5m

Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.

Author: Toby Lewis, editor, Global Corporate Venturing

Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, have helped UK-basedcell therapy developer Cell Medica raise £17m ($26.5m).

The Cancer Prevention and Research Institute of Texas has also offered $15.3m to back Cell Medica's cancer immunotherapy technology licensed from Baylor College of Medicine.

Thomas Hecht, the former vice president of marketing in Europe for Amgen is becoming chairman and UK-based foundation the Wellcome Trust is converting its investment in the company into equity.

Copyright Mawsonia Limited 2010. Please don´t cut articles from www.globaluniversityventuring.com or the PDF and redistribute by email or post to the web without written permission.

  • Linkedin
  • Mail
  • Rssfeed